argenx SE

Good morning. My name is Audra and I will be your conference operator today. At this time, I would like to welcome everyone to the Argenic second quarter 2024 financial results conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. At this time, I'd like to turn the conference over to Investor Relations, Beth Dalgiaco. Please go ahead. Thank you.

A press release was issued earlier today with our half-year 2024 financial results and second quarter business update. This can be found on our website along with the presentation for today's webcast. Before we begin, I would like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory timelines, the potential success of our product candidates, financial projections, and upcoming milestones. Actual results may differ materially from those indicated by these statements. Argenix is not under any obligation to update statements regarding the future or to confirm their statements in relation to actual results unless required by law. I'm joined on the call today by Tim Van Harmeren, Chief Executive Officer, Carl Gubitz, Chief Financial Officer, and Karen Mathey, Chief Operating Officer. I'll now turn the call over to Tim.

Thank you, Beth, and welcome, everyone. I'll begin on slide three.